{
    "clinical_study": {
        "@rank": "107442", 
        "acronym": "PRIMM", 
        "arm_group": {
            "arm_group_label": "FOLFOX + surgery + FOLFOX", 
            "arm_group_type": "Experimental", 
            "description": "Systemic chemotherapy (modified FOLFOX 4) 48 hours before surgery\nresection of the colorectal tumor during surgery\nResumption of FOLFOX within the month after surgery (post operative administration of 4 course of treatment and assessment of the response)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to analyze the clinical tolerance of immediate preoperative\n      chemotherapy in terms of toxicity and perioperative morbidity and mortality"
        }, 
        "brief_title": "Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Patients With Colorectal Cancer With Unresectable Synchronous Metastasis in Whom Resection of the Primitive Tumour is Indicated", 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  colorectal metastatic adenocarcinoma (stage IV) with unresectables, measurables and\n             visibles secondary lesions\n\n          -  primitive tumor must be operate\n\n          -  patient age between 18 and 70\n\n          -  OMS status performance < 2\n\n          -  life expectancy > 12 weeks\n\n          -  hematologic function : PNN >/= 1.5x10^9/L, platelets >/= 100x10^9/L\n\n          -  hepatic function : bilirubin </= 1.5xLSN, AST and ALT </= 3xLSN, alcalin phosphatasis\n             </= 3xLSN\n\n          -  plasmatimic creatin </= 1.25xLSN\n\n          -  No previous chemotherapy or pelvic radiotherapy\n\n          -  men and women in age of procreate agreeing  to use a contraception until 4 months\n             after the end of treatment for women and until 6 months for men\n\n        Exclusion Criteria:\n\n          -  nonmetastatic forms\n\n          -  Colorectal tumor which requires preoperative radiotherapy\n\n          -  nonmeasurable metastasis based on RECIST criteria\n\n          -  previous chemotherapy for colorectal cancer\n\n          -  previous irradiation of the primitive tumour\n\n          -  specific indication against the treatment studied\n\n          -  Patient considered as inoperable for physiological or carcinologic reasons\n\n          -  Pregnant or breast feeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01715363", 
            "org_study_id": "2011-003446-41", 
            "secondary_id": "2010/1676"
        }, 
        "intervention": [
            {
                "arm_group_label": "FOLFOX + surgery + FOLFOX", 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "FOLFOX + surgery + FOLFOX", 
                "intervention_name": "Folinic Acid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "FOLFOX + surgery + FOLFOX", 
                "intervention_name": "Fluorouracile", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Leucovorin", 
                "Folic Acid", 
                "Levoleucovorin", 
                "Oxaliplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 25, 2012", 
        "location": {
            "contact": {
                "email": "diane.goere@igr.fr", 
                "last_name": "Diane GOERE, MD", 
                "phone": "+33 1 42 11 54 41"
            }, 
            "facility": {
                "address": {
                    "city": "Villejuif", 
                    "country": "France", 
                    "state": "Val de Marne", 
                    "zip": "94805"
                }, 
                "name": "Institut Gustave Roussy"
            }, 
            "investigator": {
                "last_name": "Diane GOERE, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Feasibility of an Immediate Preoperative Chemotherapy Before Resection of Colorectal Cancer and Research of Gene Expressions Changes Induced in the Tumor, Predictive of Chemotherapy Efficiency", 
        "overall_contact": {
            "email": "diane.goere@igr.fr", 
            "last_name": "Diane GOERE, MD", 
            "phone": "+33 1 42 11 54 41"
        }, 
        "overall_contact_backup": {
            "email": "valerie.boige@igr.fr", 
            "last_name": "Val\u00e9rie BOIGE, MD", 
            "phone": "+33 1 42 11 43 11"
        }, 
        "overall_official": {
            "affiliation": "Gustave Roussy, Cancer Campus, Grand Paris", 
            "last_name": "Diane GOERE, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinical tolerance of immediate preoperative chemotherapy assessment is based on the post-operative complication rate in terms of morbidity and mortality.\nAll the post-operative complications arising within 30 days after surgery will be registered and classified using the Clavien Dindo classification", 
            "measure": "Clinical tolerance of immediate preoperative chemotherapy", 
            "safety_issue": "No", 
            "time_frame": "Assess up to 30 days after surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01715363"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Gustave Roussy, Cancer Campus, Grand Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gustave Roussy, Cancer Campus, Grand Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}